Bioxodes is a phase 2a clinical stage Biotech Company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuro-inflammation in acute hemorrhagic stroke patients.Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disease leading to high morbidity and mortality. To date, no specific or effective treatment approaches are available during the first 72 hours of onset. This critical time-window represents an opportunity for drug development, especially for drugs targeting the secondary brain injury, a major contributor to poor outcomes after ICH. Neuroinflammation, an important cause of SBI, plays a critical role in the neurologic decline of ICH patients.